Adalta (1AD: $0.155) has progressed its collaboration with GE Healthcare for its cancer treatment diagnostic.
In September Adalta signed a commercial deal with GE to find i-bodies using its unique technology that could very specifically bind to the enzyme granzyme B which is produced by activated T-cells.
Adalta has now identified several relevant i-bodies which will progress into preclinical development.